Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix (pages 3776–3783)
Alexi A. Wright, Brooke E. Howitt, Andrea P. Myers, Suzanne E. Dahlberg, Emanuele Palescandolo, Paul Van Hummelen, Laura E. MacConaill, Melina Shoni, Nikhil Wagle, Robert T. Jones, Charles M. Quick, Anna Laury, Ingrid T. Katz, William C. Hahn, Ursula A. Matulonis and Michelle S. Hirsch
Version of Record online: 23 AUG 2013 | DOI: 10.1002/cncr.28288
Cervical cancers harbor high rates of potentially targetable oncogenic mutations. In addition, squamous cell carcinoma and adenocarcinoma of the cervix have distinct molecular treatment strategies profiles, suggesting that clinical outcomes may be improved with the use of more tailored treatment strategies, including PI3K and MEK inhibitors.